Compare ECF & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ECF | ENLV |
|---|---|---|
| Founded | 1986 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.2M | 149.0M |
| IPO Year | N/A | 2014 |
| Metric | ECF | ENLV |
|---|---|---|
| Price | $12.15 | $0.73 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 23.1K | ★ 249.3K |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | ★ 6.42% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $26.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.71 | $0.43 |
| 52 Week High | $13.85 | $7.64 |
| Indicator | ECF | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 40.55 | 27.18 |
| Support Level | $12.15 | $0.72 |
| Resistance Level | $12.32 | $0.94 |
| Average True Range (ATR) | 0.16 | 0.13 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 28.77 | 2.51 |
Ellsworth Growth and Income Fund Ltd operate as a closed-end, diversified management investment company. Its investment objective is to provide income and the potential for capital appreciation, which objectives the Fund considers to be relatively equal over the long term due to the nature of the securities in which it invests. The company invests in convertible and equity securities. It invests in various sectors, such as healthcare, financial services, computer software and services, energy and utilities, real estate investment trusts, semiconductors, telecommunications, business services, food and beverage, consumer products, transportation, consumer services among others.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.